Genetic engineering of T-cell receptors: TCR takes to titin

Blood

Volumn 122, Issue 6, 2013, Pages 853-854

  Heslop, Helen E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIN; HLA ANTIGEN; MELANOMA ANTIGEN 3; NY ESO 1 ANTIGEN; T LYMPHOCYTE RECEPTOR; MUSCLE PROTEIN; PROTEIN KINASE;

AUTOPSY; CANCER IMMUNOTHERAPY; CARDIOGENIC SHOCK; CROSS REACTION; FEVER; FOLLOW UP; GENETIC ENGINEERING; HEART CELL CULTURE; HEART MUSCLE INJURY; HUMAN; LYMPHOCYTIC INFILTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SHORT SURVEY; T LYMPHOCYTE; WILD TYPE; BLOOD; CARDIOVASCULAR DISEASE; CYTOLOGY; HEART MUSCLE; MALE; METABOLISM; MULTIPLE MYELOMA; NOTE; PATHOLOGY;

CARDIOVASCULAR DISEASES; HUMANS; MALE; MELANOMA; MULTIPLE MYELOMA; MUSCLE PROTEINS; MYOCARDIUM; PROTEIN KINASES; T-LYMPHOCYTES;

EID: 84886885319     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-06-509604     Document Type: Short Survey

References (8)

1. Linette GP, Stadtmauer EA, Maus M.V., et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013; 122(6): 863-871.
2. Jorritsma A, Schotte R, Coccoris M., de Witte MA, Schumacher TN. Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther. 2011; 11(4): 276-287.
3. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012; 12(4): 269-281.
4. Schmitt TM, Aggen DH, Stromnes I.M., Dossett ML, Richman SA, Kranz DM, Greenberg PD. Enhanced-affinity murine TCRs for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection [published online ahead of print May 14, 2013]. Blood; doi: 10.1182/blood-2013-01-478164.
5. Cheever MA, Allison JP, Ferris A.S., et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009; 15(17): 5323-5337.
6. Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013; 36(2): 133-151.
7. Robbins PF, Morgan RA, Feldman S.A., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29(7): 917-924.
8. Di Stasi A., Tey SK, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011; 365(18): 1673-1683.